” Marc Beer of Renovia Inc. Spearheads Series B Funding to Finance the Treatment of Pelvic Floor Disorders in Women “

Renovia Inc. recently raised $42 million toward the establishment of a new pipeline of drugs as well as therapeutic products made to target pelvic floor disorders that affect more than 200 million women across the world. Situated in Boston, the revolutionary medtech company is seeking the support of various donors when it comes to treating disorders including urinary incontinence. In the fundraiser, $10 million was raised and channelled toward the project. $32 million was raised from a round of Series B Funding that was chaired by Perceptive Advisors alongside Ascension Ventures. The two firms are situated in New York as well as Missouri in that order. Longwood Fund was part of the project as well.

Regarding the contribution, Marc Beer, CEO of Renovia Inc stated that he was elated by this investor’s support. He added that the donation would be forwarded toward the development of drugs that would occur through the combination of the company’s proprietary form factors as well as sensor technologies. In the long-run, the idea would offer constructive data-driven treatment dockets aimed at cutting down the healthcare costs for treating pelvic floor disorders.

Renovia Inc. created Leva for pelvic floor strengthening customized to help individuals suffering from different forms of pelvic floor disorders. The healthcare system has sensor technology that is designed to allow the user to identify the position of the pelvic floor muscles during exercise. The FDA has approved the device. It has also been cleared for training patient’s weak pelvic floor muscles particularly when treating stress incontinence in addition to the moderate urge incontinence.

Marc Beer established Renovia Inc. in 2016. He is the chairman of the company and has been serving in the sector of biotechnology for over two decades. Beer is prominent for working with various companies in the same industry. They include ViaCell in which he served as the CEO and founding partner. With his guidance, the company specialized in developing as well as preserving stem cells harvested from the umbilical cord. In 2007, Beer served at PerkinElmer before acquiring it.

Additionally, he worked at Erytech Pharma which is a biopharmaceutical firm. Marc Beer also served as a member of the board of directors. Moreover, Marc Beer has worked at Genzyme where he was the VP of Global Marketing. He assisted the company to launch various brands made for treating rare diseases in the world.

Renovia Inc. was established to create and commercialize products for better diagnosis as well as treatment to improve the conditions of millions of women who suffer from pelvic floor disorders. The technology makes it possible for patients to gain access to treatment through accurate visualization of various pelvic floor movements during training. The process is also monitored to establish the results. Learn more: https://renoviainc.com/leadership/

Marc Beer Continues with his Fight against Pelvic Floor Disorders in his New Firm, Renovia Inc.

Marc Beer, the former CEO of Aegerion Pharmaceuticals has finally co-founded Renovia Inc., with the intention of developing new products that are aimed at solving the pelvic floor disorders for women. This is a very common condition that has affected and caused pain to a lot of women all over the world. Recently, the CEO of the organization was able to raise more than $42 million that will assist in the accomplishing of the organization’s objectives. The main aim is to enhance health care for women who have been suffering from the pelvic floor disorders for a very long period.

 

Renovia Inc., a company based in Boston, has developed a range of therapeutic and diagnostic products that are geared towards the treatment of pelvic floor disorders. These are health complications like the urinary incontinence. According to reliable research, this condition affects more than two hundred and fifty million women globally. To curb the spread of the disorder and also to avoid further increase of the statistic, Renovia Inc. has launched its first product that can perform the role. Leva, the new product, has obtained approval by the FDA and was launched in the market in April.

 

One of the firms that focus on healthcare, The Longwood Fund, made an early investment in Renovia. It also joined hand during the Series B round when the $42 million was raised. The funding was spearheaded by perspective advisers based in New York and the Ascension Ventures, who are located in Missouri. Their principal objective is to innovate, develop and launch several other therapeutic devices that will include enhanced innovations and advancements of the Leva gadget.

 

During an interview with the local media, Marc Beer stated that he was very grateful for the support that Renovia Inc. had received from the Longwood Fund organization and all the other stakeholders who supported the success of the Series B round. He said that it was a great honor to find out that there were a lot of people out there who shared a common agenda of resolving the agony of millions of women who have been suffering the pain of pelvic floor disorders.

 

He also stated that his team is well prepared with the right technology which will combine with other factors from the digital health platform to ensure that their customers got reasonable information and data to enable them to discover new options of treatment and also gain deeper understanding and knowledge of pelvic floor disorders. This will enable them to come up with more efficient methods to handle the disorders and subsequently lowering the general cost of health care. Learn more : https://www.slideshare.net/MarcBeer